Humedix (A200670) Stock Overview
Engages in the manufacture and sale of various pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 1/6 |
A200670 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Humedix Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩35,800.00 |
| 52 Week High | ₩77,200.00 |
| 52 Week Low | ₩33,050.00 |
| Beta | 0 |
| 1 Month Change | -20.27% |
| 3 Month Change | -9.94% |
| 1 Year Change | -7.97% |
| 3 Year Change | 55.31% |
| 5 Year Change | 45.53% |
| Change since IPO | 25.59% |
Recent News & Updates
Recent updates
Humedix (KOSDAQ:200670) Has A Pretty Healthy Balance Sheet
Mar 09
Humedix Co., Ltd.'s (KOSDAQ:200670) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 16Should You Buy Humedix Co., Ltd. (KOSDAQ:200670) For Its Dividend?
Jan 28Are Humedix's (KOSDAQ:200670) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 11
What Type Of Returns Would Humedix's(KOSDAQ:200670) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 22Here's Why Humedix (KOSDAQ:200670) Can Manage Its Debt Responsibly
Dec 01Shareholder Returns
| A200670 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0% | 10.7% | -4.8% |
| 1Y | -8.0% | 73.1% | 103.7% |
Return vs Industry: A200670 underperformed the KR Pharmaceuticals industry which returned 73.1% over the past year.
Return vs Market: A200670 underperformed the KR Market which returned 103.7% over the past year.
Price Volatility
| A200670 volatility | |
|---|---|
| A200670 Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in KR Market | 15.7% |
| 10% least volatile stocks in KR Market | 4.4% |
Stable Share Price: A200670 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A200670's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Min-jong Kang | humedix.com |
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs.
Humedix Co., Ltd. Fundamentals Summary
| A200670 fundamental statistics | |
|---|---|
| Market cap | ₩369.98b |
| Earnings (TTM) | ₩9.06b |
| Revenue (TTM) | ₩110.99b |
Is A200670 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A200670 income statement (TTM) | |
|---|---|
| Revenue | ₩110.99b |
| Cost of Revenue | ₩66.92b |
| Gross Profit | ₩44.07b |
| Other Expenses | ₩35.00b |
| Earnings | ₩9.06b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A200670 perform over the long term?
See historical performance and comparisonDividends
Does A200670 pay a reliable dividends?
See A200670 dividend history and benchmarks| Humedix dividend dates | |
|---|---|
| Ex Dividend Date | Apr 02 2026 |
| Dividend Pay Date | Apr 22 2026 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 25 days |
Does A200670 pay a reliable dividends?
See A200670 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/27 13:51 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Humedix Co., Ltd. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Jin | Daiwa Securities Co. Ltd. |
| null null | DBS Bank Ltd |
| Sang-Hun Lee | iM Securities |